Helicobacter Pylori 23S rRNA/gyrA Gene Mutation Detection Kit (Fluorescence PCR Fusion Curve Method)

CompletedOBSERVATIONAL
Enrollment

1,176

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

September 12, 2023

Study Completion Date

October 1, 2023

Conditions
Helicobacter Pylori InfectionHelicobacter Pylori gyrA Levofloxacin Resistance MutationFecal Drug Resistance Gene DetectionHelicobacter Pylori Infection, Susceptibility to
Interventions
DIAGNOSTIC_TEST

Detection of fecal samples with diagnostic kit

The 23S rRNA mutation site of clarithromycin and gyrA mutation site of levofloxacin were detected by Helicobacter Pylori fecal Gene Mutation Detection Kit.

DIAGNOSTIC_TEST

Sanger Sequencing group

Detection of gyrA and 23S rRNA mutations in H. pylori isolated from Gastric Mucosa by Sanger Sequencing

DIAGNOSTIC_TEST

Bacterial culture and drug sensitivity test of gastric mucosa samples

First, a sample of the patient's gastric mucosa will be obtained through gastroscopy. Then, Helicobacter pylori culture and drug sensitivity test can be carried out. Finally, the resistance data of Helicobacter pylori to clarithromycin and levofloxacin will be obtained.

Trial Locations (4)

210000

Nanjing First Hospital, Nanjing Medical University, Nanjing

225300

Jiangsu Taizhou People's Hospital, Taizhou

310003

The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou

330000

The First Affiliated Hospital of Nanchang University, Nanchang

All Listed Sponsors
lead

Nanjing First Hospital, Nanjing Medical University

OTHER